Skip to main content

Registration
IDWeek Learning Objective
Return to Sessions
and Exhibits
Chasing the Sun
Schedule
Speakers
Oral Abstracts
Posters
Featured Speakers
FAQ

IDWeek 2020 Main banner

Registration
IDWeek Learning Objective
Return to Sessions
and Exhibits
Chasing the Sun
Schedule
Speakers
Oral Abstracts
Posters
Featured Speakers
FAQ

Tweets by IDWeek 2020

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Chasing the Sun

Live

On Demand

Favorite
0 Like
Facebook
Tweet this
Print

C. Andrew DeRyke, PharmD

Global Director Medical Affairs
Merck & Co., Inc.

Disclosure: Merck & Co., Inc. (Employee, Shareholder)

Poster(s):

103 - Empiric Antibiotic Susceptibility Using a Traditional vs. Syndromic Antibiogram-Implications for Antimicrobial Stewardship Programs
1230 - Clinical and Microbiologic Outcomes by Causative Pathogen in Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Treated with Imipenem/Cilastatin (IMI)/Relebactam (REL) Versus Piperacillin/Tazobactam (PIP/TAZ)
1450 - Frequency of Carbapenem-resistant Pseudomonas aeruginosa Among Respiratory Pathogens Impacts First-Line Beta-Lactam Susceptibility: Potential Role for Ceftolozane/Tazobactam (C/T) and/or Imipenem/Relebactam (I/R)
1460 - Imipenem/Cilastatin (IMI)/Relebactam (REL) in Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia (HABP/VABP): Subgroup Analyses of Critically Ill Patients in the RESTORE-IMI 2 Trial
1603 - Comparison of Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Meropenem/Vaborbactam Activity Against P. aeruginosa: A Multicenter Evaluation

Designed by CadmiumCD |Technical Support |Give Feedback
© Copyright 2024 CadmiumCD. All Rights Reserved.